Genetic Engineering & Biotechnology NewsImmunotherapy Response Predicted by Liquid BiopsyGenetic Engineering & Biotechnology News"We can help predict response to immunotherapy by measuring the number of mutations in circulating tumor DNA [ctDNA] u… Continue reading
Genetic Engineering & Biotechnology News |
Immunotherapy Response Predicted by Liquid Biopsy
Genetic Engineering & Biotechnology News “We can help predict response to immunotherapy by measuring the number of mutations in circulating tumor DNA [ctDNA] using a simple blood test,” said Yulian Khagi, M.D., University of California San Diego Moores Cancer Center fellow and first author. DNA mutations shed in blood predicts response to immunotherapy in patients with cancerMedical Xpress DNA mutations in blood predict response to immunotherapyUPI.com Study Demonstrates Potential for the Guardant360 Assay® to Predict Which Patients Will Benefit from ImmunotherapyMarkets Insider |
Endpoints News |
Sam Kulkarni takes the helm at CRISPR Therapeutics as founding CEO steps down
Endpoints News After steering CRISPR Therapeutics to an IPO last year as the last of the big three gene editing companies to make the leap into the public markets, founding CEO Rodger Novak is stepping down and handing the reins over to the original chief business … CRISPR Therapeutics Announces Promotion of Samarth Kulkarni, Ph.D. to Chief Executive OfficerGlobeNewswire (press release) Somewhat Favorable News Coverage Somewhat Unlikely to Impact CRISPR THERAPTC (CRSP) Share PriceWeek Herald Equity Research Analyst’s Stock Ratings: TiVo Corporation (TIVO), CRISPR Therapeutics AG (CRSP)Analyst Journal BangaloreWeekly all 6 news articles » |
|
Atossa Genetics Announces Chimeric Antigen Receptor Therapy (CAR–T) Program in Breast Cancer
Nasdaq We believe that our proprietary TRAP technology could provide a potentially safer yet effective method to deliver CAR-T,” stated Steven Quay, MD, PhD, Atossa CEO. “We believe that TRAP CAR-T, as we are calling this novel approach to adaptive T–cell … |
|
Atossa Genetics Announces Chimeric Antigen Receptor Therapy (CAR–T) Program in Breast Cancer
GlobeNewswire (press release) We believe that our proprietary TRAP technology could provide a potentially safer yet effective method to deliver CAR-T,” stated Steven Quay, MD, PhD, Atossa CEO. “We believe that TRAP CAR-T, as we are calling this novel approach to adaptive T–cell … |
SFGate |
‘Super exciting’ results in stem cell therapy trial
SFGate Four out of six paralyzed patients who had 10 million stem cells transplanted into their spinal cords have shown striking improvement a year after treatment, including increased ability to move their hands and arms and to perform basic functions like … |